Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Overview
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Companies Involved in Therapeutics Development
Adamed Sp zoo
Alla Chem LLC
Avineuro Pharmaceuticals Inc
Celon Pharma SA
Denovo Biopharma LLC
HEC Pharma Co Ltd
Reviva Pharmaceuticals Inc
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Drug Profiles
ADN-1184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-2013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-3662 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-3208 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-3205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-322 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-492 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilaroxazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HEC-30654AcOH - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idalopirdine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pirdinenserin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT6 for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT6 Receptor for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Dormant Products
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Discontinued Products
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Product Development Milestones
Featured News & Press Releases
Jul 01, 2021: Denovo Biopharma in-licenses late-stage Alzheimer’s Disease asset from Lundbeck
Apr 26, 2021: Reviva announces full details of positive phase 2 clinical trial results for acute Schizophrenia
Oct 09, 2019: ChemRar Group of Companies announces the successful completion of the second phase of clinical trials of an innovative drug for the treatment of generalized anxiety disorder
Jun 03, 2019: Reviva Pharmaceuticals announces successful completion of pre-IND meeting with FDA on Brilaroxazine for the treatment of idiopathic pulmory fibrosis
Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Desigtion for RP5063 for the Treatment of Idiopathic Pulmory Fibrosis (IPF)
Jan 10, 2018: Avineuro Pharmaceuticals Reported Phase Ib Trial Results of AVN-101
Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmory Arterial Hypertension
Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Desigtion for Pulmory Arterial Hypertension (PAH)
Sep 22, 2016: Headline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer’s disease
Jul 07, 2016: Idalopirdine granted Fast Track Desigtion by U.S. Food and Drug Administration (FDA)
May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmory Arterial Hypertension at the American Thoracic Society Conference 2016
Apr 11, 2016: Lundbeck to Present Data on Idalopirdine at American Academy of Neurology
Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits
Jul 01, 2015: Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist
Dec 14, 2014: AllaChem Completes Phase Ib/IIa Clinical Study with AV4025, an HCV NS5A Inhibitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Adamed Sp zoo, 2021
Pipeline by Alla Chem LLC, 2021
Pipeline by Avineuro Pharmaceuticals Inc, 2021
Pipeline by Celon Pharma SA, 2021
Pipeline by Denovo Biopharma LLC, 2021
Pipeline by HEC Pharma Co Ltd, 2021
Pipeline by Reviva Pharmaceuticals Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Discontinued Products, 2021